Shares in US biotech Sarepta Therapeutics (Nasdaq: SRPT) lost 19% of their value on Monday and Tuesday following the presentation of new trial results at the 40th Annual JP Morgan Healthcare Conference.
Sarepta announced top-line results from Part 2 of the study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (delandistrogene moxeparvovec) in 41 patients with Duchenne muscular dystrophy (DMD), 21 of whom were in the placebo crossover cohort.
"SRP-9001 is the greatest near-term hope we all have to address the need for a therapy that changes the trajectory of this disease"This investigational gene transfer therapy is intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. SRP-9001-treated participants from the placebo crossover group scored a statistically-significant 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) at 48 weeks compared to propensity-score weighted external controls.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze